Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD – Get Free Report) was the recipient of a large decline in short interest in January. As of January 31st, there was short interest totalling 11,500 shares, a decline of 79.1% from the January 15th total of 55,100 shares. Based on an average daily volume of 185,500 shares, the short-interest ratio is currently 0.1 days. Currently, 0.3% of the company’s stock are sold short.
Analysts Set New Price Targets
Separately, StockNews.com began coverage on Galmed Pharmaceuticals in a report on Monday. They set a “sell” rating for the company.
Galmed Pharmaceuticals Trading Up 2.8 %
Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) last released its earnings results on Wednesday, November 22nd. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter.
Hedge Funds Weigh In On Galmed Pharmaceuticals
Several institutional investors have recently bought and sold shares of the company. Cambridge Investment Research Advisors Inc. purchased a new position in Galmed Pharmaceuticals in the first quarter valued at approximately $42,000. Raymond James Financial Services Advisors Inc. lifted its stake in Galmed Pharmaceuticals by 158.9% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 63,310 shares of the biopharmaceutical company’s stock valued at $101,000 after purchasing an additional 38,856 shares during the last quarter. Millennium Management LLC lifted its stake in Galmed Pharmaceuticals by 372.3% in the second quarter. Millennium Management LLC now owns 50,748 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 40,003 shares during the last quarter. Finally, Walleye Capital LLC purchased a new position in Galmed Pharmaceuticals in the third quarter valued at approximately $155,000. Hedge funds and other institutional investors own 20.89% of the company’s stock.
Galmed Pharmaceuticals Company Profile
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
- Five stocks we like better than Galmed Pharmaceuticals
- The Most Important Warren Buffett Stock for Investors: His Own
- 3 attractive stocks that insiders are buying
- What Does a Stock Split Mean?
- Alpha and Omega Semiconductor ready to bounce, DOJ cloud lifts
- Transportation Stocks Investing
- Wendy’s vs Shake Shack: Out with the new, in with the old?
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.